Marko Salmikangas

Affiliations

Laboratory of Molecular Oncology, Biomedicum, University of Helsinki, Helsinki, Finland.

Publications (4)

A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.

Molecular cancer therapeutics

Avec: Vadim Le Joncour , Ana Martins , Maija Puhka , Jorma Isola , Marko Salmikangas , Pirjo Laakkonen , Heikki Joensuu , Mark Barok

Neurocan expression associates with better survival and viral positivity in Merkel cell carcinoma.

PloS one

Avec: Marko Salmikangas , Maria Laaksonen , Henrik Edgren , Marco Salgado , Anu Suoranta , Pirkko Mattila , Virve Koljonen , Tom Böhling , Harri Sihto

ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.

Cancer letters

Avec: Mark Barok , Vadim Le Joncour , Ana Martins , Jorma Isola , Marko Salmikangas , Pirjo Laakkonen , Heikki Joensuu

ALK is frequently phosphorylated in Merkel cell carcinoma and associates with longer survival.

PloS one

Avec: Jenni Jaatinen , Tuukka Veija , Marko Salmikangas , Tom Böhling , Harri Sihto , Virve Koljonen

Réseau de co-auteurs

Vadim Le Joncour 2 collaborations

Ana Martins 2 collaborations

Jorma Isola 2 collaborations

Pirjo Laakkonen 2 collaborations

Heikki Joensuu 2 collaborations

Mark Barok 2 collaborations

Virve Koljonen 2 collaborations

Tom Böhling 2 collaborations

Harri Sihto 2 collaborations

Maija Puhka 1 collaboration

Maria Laaksonen 1 collaboration

Henrik Edgren 1 collaboration

Marco Salgado 1 collaboration

Anu Suoranta 1 collaboration

Pirkko Mattila 1 collaboration

Jenni Jaatinen 1 collaboration

Tuukka Veija 1 collaboration